LXRX logo

LEXICON PHARMACEUTICALS INC

LXRXNASDAQ
🏆 #2692 by market capEarnings Nov 11US Equity
$1.42▼ $0.07 (−5.03%)
Latest quote
🔔
Track LXRX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.0%
7d▲ 0.4%
14d▼ 6.9%
30d▼ 24.3%
ytd▲ 24.7%
1y▲ 6.0%
🏦Market Cap
$630M
Small Cap
📈Revenue Growth (YoY)
-29.0%
Declining
📊Gross Margin
99.1%
High
💵FCF Margin
41.0%
Strong
⚖️P/S Ratio
16.0x
Expensive
Otter Score
48
Weak

Trading Snapshot

Day Range
$1.41 – $1.50
52-Week Range
$1.10 – $2.68
Volume (shares)
40,215
Avg Volume (shares)
—
Shares Outstanding
445.0M
Next Earnings
2026-11-11

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
16.0x
EPS (TTM)
$-0.15
Dividend Yield
—
Dilution (1yr)
+0.5%
LXRX logo

LEXICON PHARMACEUTICALS INC

LXRX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$50M▲ +60.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
99.4%▲ +1.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$49M▼ −75.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$68M▼ −62.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
363.4M▲ +0.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$28M▲ +$14M YoY
StockOtter · stockotter.space

About LEXICON PHARMACEUTICALS INC

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
48/100

Analyst Ratings

ⓘ
Consensus
Buy
12 analysts
Strong Buy3
Buy6
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.